Researchers presented new findings Saturday at a breast-cancer symposium here suggesting that the risks associated with anthracyclines, a class of chemotherapy drugs widely used to treat the disease, outweighed their benefits in some patients.The findings renewed a debate over whether anthracyclines, which have been around since the 1960s, should remain the standard of care in treating breast cancer, or whether newer drugs should be used more frequently instead.
More...
By the time the American surgeon who contracted Ebola in Congo was flown to Germany for...
The Trump administration has announced a plan to kill Biden-era drinking water limits on four Pfas...
Yet another item that may be in your pantry has been recalled over possible salmonella contamination.
A...
